alpha-Interferon in hematological malignancies.
Recent studies have generated data demonstrating significant clinical activity of alpha-interferon therapy in each of six hematological malignancies, chronic myeloid leukaemia, essential thrombocythemia, polycythemia rubra vera, non-Hodgkin's lymphomas, multiple myelomatosis and hairy cell leukaemia.
Giles
F J
FJ
Division of Medical Oncology, School of Medicine, University of North Carolina, Chapel Hill 27599-7305.
Ozer
H
H
D006801:Humans; D016898:Interferon-alpha / Q000502:physiology / Q000627:therapeutic use*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D007943:Leukemia, Hairy Cell / Q000276:immunology / Q000628:therapy; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology / Q000628:therapy; D009101:Multiple Myeloma / Q000276:immunology / Q000628:therapy; D013920:Thrombocythemia, Essential / Q000276:immunology / Q000628:therapy
D016898:Interferon-alpha